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We investigated 28 cases of bacteremia caused by Capnocytophaga species that occurred during an 8-year period, most of which were in patients with hematologic malignancy and neutropenia. Infections were uncomplicated, without serious organ involvement and without any apparent source except ulcerations of the oropharyngeal mucosa, and only 1 isolate showed resistance to b-lactam antibiotics; 9 of 16 isolates were resistant to ciprofloxacin.
Capnocytophaga species are a rare cause of bacteremia in patients with neutropenia and cancer. The frequency with which these bacteria have been isolated in large patient series ranges from 0.5% to 3% [1, 2] . Capnocytophaga species are facultatively anaerobic gram-negative bacilli that are part of the normal oral flora, and it has been suggested that bloodstream infections develop when Capnocytophaga break through the normal mucosal barrier in patients who have severe oropharyngeal mucositis or periodontal disease [2] [3] [4] . Historically, Capnocytophaga isolates have been susceptible to most groups of antibiotics used to treat patients with neutropenia and cancer, including b-lactam antibiotics and the fluorinated quinolones [5] [6] [7] . However, in recent years some strains have been isolated from such patients that have resistance to b-lactams, presumably induced by previous exposure to these agents [2, 4, 8] . To date, resistance to fluoroquinolones has been reported for only 1 multidrug-resistant strain [8] . We report results of a retrospective study of bacteremia caused by Capnocytophaga species in patients with cancer who were seen at 4 tertiary hospitals in Spain during the period 1992-2000.
Patients and methods. Clinical data were collected retrospectively for all consecutive patients with cancer who had у1 blood culture positive for Capnocytophaga species during a febrile episode within the study period at 3 of the 4 participating institutions; at 1 hospital (Hospital de la Santa Creu i Sant Pau, Barcelona), data had been collected prospectively. Routine processing of blood cultures and methods of bacterial isolation and identification varied slightly between institutions and over time, but antibiotic susceptibility testing was done in all cases by use of an agar plate dilution technique with WilkinsChalgar agar, as recommended by the National Committee for Clinical Laboratory Standards [9] . The MIC was defined as the lowest concentration of antibiotic that completely inhibited growth, and resistance was defined as an MIC greater than a specified concentration for each antibiotic tested [4] [5] [6] 9] . Results. Table 1 summarizes the characteristics of the 28 patients with bacteremia. Most of the patients (89%) had a hematologic malignancy, and all had recently received myelotoxic chemotherapy for their malignancy; 46% had undergone a hematopoietic stem cell transplantation. Most patients (93%) had neutropenia at the time of infection, and moderate-tosevere oropharyngeal mucositis was reported for one-half of the patients. All 28 patients had fever at the time of bacteremia. None of the patients, however, had clinical or radiologic signs of a serious deep-tissue infection; therefore, all cases were uncomplicated bacteremia. There were no catheter-related infections. All cases of bacteremia responded to antibiotic therapy: a broad-spectrum b-lactam in 18 cases, a carbapenem in 7 cases, fluoroquinolones in 2 cases, and clindamycin in 1 case.
Thirteen patients had received systemic antibiotic therapy within the 30 days before the onset of Capnocytophaga bacteremia. Table 2 shows the antibiotic susceptibility of the isolates. Four patients had previously received a b-lactam antibiotic, and the isolate recovered from 1 of these patients was resistant to b-lactams. Of the strains recovered from the 28 patients, this was the only one resistant to these b-lactams. Sixteen isolates were tested for in vitro susceptibility to fluoroquinolones, and 9 (56%) were resistant to ciprofloxacin. There was no apparent relationship between recent treatment with a fluoroquinolone and the resistance of the isolate to fluoroquinolones (see table   2 ). All isolates were resistant to aminoglycosides, as reported elsewhere [3, 5] .
Discussion. Our study shows that Capnocytophaga bacteremia in this patient population is usually an uncomplicated infection without serious organ involvement and without any apparent source except ulcerations of the oropharyngeal mucosa, and that it has a good outcome after antibiotic therapy. Unlike other authors [2, 4] , we found only 1 isolate that was resistant to b-lactam antibiotics. However, more than one-half of the tested isolates were resistant to ciprofloxacin. Previous studies showed that these bacteria were uniformly susceptible in vitro to the fluorinated quinolones [2, 4, 5] .
On the basis of our results and those reported in other studies, we consider that patients with neutropenia who have Capnocytophaga bacteremia can be safely managed by administering monotherapy with a broad-spectrum b-lactam antibiotic, especially a carbapenem or an ureidopenicillin with a b-lactamase inhibitor. Aminoglycosides are not effective against this infection, and our data indicate that fluoroquinolones should be used only if the isolate is susceptible in vitro. If a strain that is resistant to b-lactams is isolated, clindamycin can be added to the antibiotic regimen (this antibiotic is active against strains that produce b-lactamase) [2, [4] [5] [6] . Because the growth and identification of Capnocytophaga species in vitro requires at least 48 h, one of these strategies should be followed once fusiform gram-negative bacilli have been identified in blood cultures by direct examination.
